Streetbeat News

Products Services

GM

General Motors (GM) is seeking a level playing field against Chinese EV makers, as stated by President Mark Reuss. The company is concerned about China's pricing strategies and the impact on local players. The Biden administration has increased tariffs on Chinese EVs, further restricting their entry into the U.S. market. GM's EV sales dropped 20.5% year-on-year in Q1 2024, largely due to the discontinuation of the Chevrolet Bolt. GM recently launched the Chevrolet Equinox EV, aiming to compete with Tesla's Model Y.

Portfolio Pulse from Anan Ashraf

May 16, 2024 | 11:48 am

GAMB

Gambling.com Group has revised its FY24 revenue forecast downwards from $129M-$133M to $118M-$122M, citing changes in Google's treatment of commercial content on high authority websites. This adjustment impacts the effectiveness of the company's media partnerships.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:48 am

CARM

Carisma Therapeutics has dosed the first patient in a Phase 1 clinical trial of CT-0525, a novel HER2-targeting CAR-Monocyte. This is the first CAR-Monocyte to be evaluated in humans for solid tumors, with initial data expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:43 am

AGEN

Agenus Inc. (NASDAQ:AGEN) will hold a Type B End-of-Phase 2 meeting with the FDA in July to discuss its BOT/BAL therapy for relapsed/refractory metastatic colorectal cancer. The meeting aims to expedite the development and support a future BLA submission.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:40 am

LILM

Lilium N.V. (NASDAQ:LILM) has started construction of an advanced test facility for the Lilium Jet in partnership with SEGULA Technologies. The facility, located near Munich, Germany, will be operational by late Summer 2024 and will be used for integration and certification testing of the Lilium Jet.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:38 am

REE

REE Automotive announced that its P7-C electric trucks and platforms have been approved for a $30,000 incentive per vehicle in Massachusetts.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:38 am

BIIB

IONS

Ionis Pharmaceuticals and Biogen have announced the discontinuation of the development of BIIB105 based on data from a Phase 1/2 study.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:36 am

AXGN

Axogen has initiated the rolling submission process with the FDA for a Biologics License Application (BLA) for its Avance Nerve Graft. The company expects to complete the BLA filing by Q3 2024 and anticipates approval around mid-2025.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:34 am

JNJ

Johnson & Johnson (NYSE:JNJ) announced its acquisition of Proteologix, Inc. for $850 million in cash, with potential milestone payments. Proteologix specializes in bispecific antibodies for immune-mediated diseases, including atopic dermatitis and asthma.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:33 am

MTNB

Matinas BioPharma presented new in vitro data at TIDES USA 2024, demonstrating their LNC platform's ability to deliver small oligonucleotides.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:32 am